Targeted Agents: The Rules of Combination
The success of molecularly targeted agents (MTA) in the treatment of cancer has led to the investigation of their use in combination with other MTAs and with conventional chemotherapies. An overview of the MTAs that have emerged as Food and Drug Administration–approved drugs is presented, along with...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2007-09, Vol.13 (18), p.5232-5237 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5237 |
|---|---|
| container_issue | 18 |
| container_start_page | 5232 |
| container_title | Clinical cancer research |
| container_volume | 13 |
| creator | KWAK, Eunice L CLARK, Jeffrey W CHABNER, Bruce |
| description | The success of molecularly targeted agents (MTA) in the treatment of cancer has led to the investigation of their use in combination
with other MTAs and with conventional chemotherapies. An overview of the MTAs that have emerged as Food and Drug Administration–approved
drugs is presented, along with a framework for the consideration of how MTAs can best be combined to maximize therapeutic
effect. |
| doi_str_mv | 10.1158/1078-0432.CCR-07-1385 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68279789</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68279789</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-cfebcf9a233989b9fe9b5d53bf74cdfea3d32a1c4191f34b8fa387ffa7363d553</originalsourceid><addsrcrecordid>eNpF0N9LwzAQB_AgipvTP0Hpi8IeOpOmWRLfRvEXDIQxn0OaXtZK186kRfzvTVllT3cPn7vjvgjdErwghIlHgrmIcUqTRZZtYsxjQgU7Q1PCGI9psmTnof83E3Tl_RfGJCU4vUQTwgVnPJVTNN9qt4MOimi1g6bzT9G2hGjT1-Cj1kZZu8-rRndV21yjC6trDzdjnaHPl-dt9havP17fs9U6NikRXWws5MZKnVAqhcylBZmzgtHc8tQUFjQtaKJJwJJYmubCaiq4tZrTJS0YozP0cNx7cO13D75T-8obqGvdQNt7tRQJl1zIANkRGtd678Cqg6v22v0qgtWQkRr-V8P_KmSkMFdDRmHubjzQ53soTlNjKAHcj0B7o2vrdGMqf3KSLFOc4ODmR1dWu_KncqBMkOAceNDOlOGcIkKxhCb0DwZXfIo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68279789</pqid></control><display><type>article</type><title>Targeted Agents: The Rules of Combination</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>KWAK, Eunice L ; CLARK, Jeffrey W ; CHABNER, Bruce</creator><creatorcontrib>KWAK, Eunice L ; CLARK, Jeffrey W ; CHABNER, Bruce</creatorcontrib><description>The success of molecularly targeted agents (MTA) in the treatment of cancer has led to the investigation of their use in combination
with other MTAs and with conventional chemotherapies. An overview of the MTAs that have emerged as Food and Drug Administration–approved
drugs is presented, along with a framework for the consideration of how MTAs can best be combined to maximize therapeutic
effect.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-07-1385</identifier><identifier>PMID: 17875749</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; combination therapy ; Drug Approval ; Drug Resistance, Neoplasm ; Humans ; Medical sciences ; molecularly targeted agents ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Pharmacology. Drug treatments ; United States ; United States Food and Drug Administration</subject><ispartof>Clinical cancer research, 2007-09, Vol.13 (18), p.5232-5237</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-cfebcf9a233989b9fe9b5d53bf74cdfea3d32a1c4191f34b8fa387ffa7363d553</citedby><cites>FETCH-LOGICAL-c418t-cfebcf9a233989b9fe9b5d53bf74cdfea3d32a1c4191f34b8fa387ffa7363d553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3356,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19164020$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17875749$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KWAK, Eunice L</creatorcontrib><creatorcontrib>CLARK, Jeffrey W</creatorcontrib><creatorcontrib>CHABNER, Bruce</creatorcontrib><title>Targeted Agents: The Rules of Combination</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>The success of molecularly targeted agents (MTA) in the treatment of cancer has led to the investigation of their use in combination
with other MTAs and with conventional chemotherapies. An overview of the MTAs that have emerged as Food and Drug Administration–approved
drugs is presented, along with a framework for the consideration of how MTAs can best be combined to maximize therapeutic
effect.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>combination therapy</subject><subject>Drug Approval</subject><subject>Drug Resistance, Neoplasm</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>molecularly targeted agents</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Pharmacology. Drug treatments</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0N9LwzAQB_AgipvTP0Hpi8IeOpOmWRLfRvEXDIQxn0OaXtZK186kRfzvTVllT3cPn7vjvgjdErwghIlHgrmIcUqTRZZtYsxjQgU7Q1PCGI9psmTnof83E3Tl_RfGJCU4vUQTwgVnPJVTNN9qt4MOimi1g6bzT9G2hGjT1-Cj1kZZu8-rRndV21yjC6trDzdjnaHPl-dt9havP17fs9U6NikRXWws5MZKnVAqhcylBZmzgtHc8tQUFjQtaKJJwJJYmubCaiq4tZrTJS0YozP0cNx7cO13D75T-8obqGvdQNt7tRQJl1zIANkRGtd678Cqg6v22v0qgtWQkRr-V8P_KmSkMFdDRmHubjzQ53soTlNjKAHcj0B7o2vrdGMqf3KSLFOc4ODmR1dWu_KncqBMkOAceNDOlOGcIkKxhCb0DwZXfIo</recordid><startdate>20070915</startdate><enddate>20070915</enddate><creator>KWAK, Eunice L</creator><creator>CLARK, Jeffrey W</creator><creator>CHABNER, Bruce</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070915</creationdate><title>Targeted Agents: The Rules of Combination</title><author>KWAK, Eunice L ; CLARK, Jeffrey W ; CHABNER, Bruce</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-cfebcf9a233989b9fe9b5d53bf74cdfea3d32a1c4191f34b8fa387ffa7363d553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>combination therapy</topic><topic>Drug Approval</topic><topic>Drug Resistance, Neoplasm</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>molecularly targeted agents</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Pharmacology. Drug treatments</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KWAK, Eunice L</creatorcontrib><creatorcontrib>CLARK, Jeffrey W</creatorcontrib><creatorcontrib>CHABNER, Bruce</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KWAK, Eunice L</au><au>CLARK, Jeffrey W</au><au>CHABNER, Bruce</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted Agents: The Rules of Combination</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2007-09-15</date><risdate>2007</risdate><volume>13</volume><issue>18</issue><spage>5232</spage><epage>5237</epage><pages>5232-5237</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>The success of molecularly targeted agents (MTA) in the treatment of cancer has led to the investigation of their use in combination
with other MTAs and with conventional chemotherapies. An overview of the MTAs that have emerged as Food and Drug Administration–approved
drugs is presented, along with a framework for the consideration of how MTAs can best be combined to maximize therapeutic
effect.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>17875749</pmid><doi>10.1158/1078-0432.CCR-07-1385</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2007-09, Vol.13 (18), p.5232-5237 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68279789 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences combination therapy Drug Approval Drug Resistance, Neoplasm Humans Medical sciences molecularly targeted agents Neoplasms - drug therapy Neoplasms - metabolism Pharmacology. Drug treatments United States United States Food and Drug Administration |
| title | Targeted Agents: The Rules of Combination |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T04%3A07%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20Agents:%20The%20Rules%20of%20Combination&rft.jtitle=Clinical%20cancer%20research&rft.au=KWAK,%20Eunice%20L&rft.date=2007-09-15&rft.volume=13&rft.issue=18&rft.spage=5232&rft.epage=5237&rft.pages=5232-5237&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-07-1385&rft_dat=%3Cproquest_cross%3E68279789%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68279789&rft_id=info:pmid/17875749&rfr_iscdi=true |